About This Research

The Safety and Efficacy of Fluoxetine for the Treatment of Refractory Primary Monosymptomatic Nocturnal Enuresis in Children: A Randomized Placebo-Controlled Trial

Bedwetting, medically known as nocturnal enuresis, is one of the most common childhood disorders, affecting millions of children worldwide. While many children outgrow the condition naturally, a significant proportion continue to experience persistent nighttime urinary incontinence, leading to psychological distress, reduced self-esteem, social difficulties, and emotional burdens for both children and their families.

Primary Monosymptomatic Nocturnal Enuresis (PMNE) represents a specific form of bedwetting that occurs in otherwise healthy children without daytime urinary symptoms or underlying neurological or anatomical abnormalities. Despite the availability of several treatment options, many children remain resistant to conventional therapies, highlighting the need for safe and effective alternative treatment strategies.

Addressing this important clinical challenge, researchers from the Department of Urology at Mansoura Urology and Nephrology Center, Mansoura University, conducted the first randomized placebo-controlled clinical trial investigating the safety and efficacy of Fluoxetine in children with refractory PMNE. The study was published in The Journal of Urology, one of the world's most prestigious peer-reviewed journals in the field of urology.

Study Overview

This groundbreaking clinical trial explored the potential role of Fluoxetine, a selective serotonin reuptake inhibitor (SSRI) widely used in the treatment of depression and anxiety disorders, as a novel therapeutic option for children suffering from treatment-resistant primary monosymptomatic nocturnal enuresis.

The research was designed as a randomized placebo-controlled study, the gold standard for evaluating treatment efficacy and safety. Researchers compared Fluoxetine treatment with placebo in children who had not responded adequately to conventional therapeutic approaches.

The study investigated treatment outcomes, response rates, safety parameters, and the overall clinical effectiveness of Fluoxetine in reducing nocturnal enuresis episodes. By examining both efficacy and tolerability, the research aimed to determine whether Fluoxetine could offer a practical and safe alternative for children with refractory disease.

What You Will Learn in This Video

This research provides a comprehensive overview of the causes, challenges, and treatment limitations associated with Primary Monosymptomatic Nocturnal Enuresis (PMNE) in children.

Through a detailed explanation of the clinical trial design, methodology, and outcomes, viewers will gain valuable insights into how Fluoxetine may influence bladder control mechanisms and improve treatment outcomes in children with resistant nocturnal enuresis.

The presentation also discusses the psychological and social impact of bedwetting, current therapeutic approaches, and the rationale behind repurposing Fluoxetine as a novel treatment option for a condition that continues to affect the quality of life of many children and families worldwide.

Key Findings

• Novel Therapeutic Strategy: The study investigated Fluoxetine as a potential new treatment option for children with refractory Primary Monosymptomatic Nocturnal Enuresis.

• Randomized Controlled Design: The research employed a placebo-controlled methodology, providing a high level of scientific evidence regarding treatment efficacy and safety.

• Clinical Improvement: Fluoxetine demonstrated promising therapeutic effects in reducing nocturnal enuresis episodes among treatment-resistant children.

• Favorable Safety Profile: As an established SSRI with a well-documented safety record in pediatric populations, Fluoxetine showed acceptable tolerability during treatment.

• Potential Practice Impact: Findings suggest that Fluoxetine may represent a valuable alternative therapeutic option for selected patients who fail to respond to conventional treatments.

Why This Study Matters

Although nocturnal enuresis is often considered a benign childhood condition, its impact extends far beyond nighttime symptoms. Persistent bedwetting can affect emotional well-being, academic performance, social development, and family dynamics. For children who do not respond to standard treatments, the therapeutic options become increasingly limited.

This study introduces a promising evidence-based approach to managing refractory PMNE by evaluating medication with an established safety profile and broad clinical experience. The findings expand treatment options for pediatric patients and provide clinicians with valuable data on the potential role of Fluoxetine in managing treatment-resistant nocturnal enuresis.

Beyond its clinical implications, this research highlights the importance of therapeutic innovation and drug repurposing in pediatric urology, offering new perspectives for future investigations and improved patient care.

Who Should Watch This Research Presentation?

This research presentation is particularly valuable for:

• Pediatric Urologists and Urology Specialists seeking evidence-based approaches for treatment-resistant nocturnal enuresis.

• Pediatricians managing children with persistent bedwetting and urinary disorders.

• Child Psychiatrists and Mental Health Professionals are interested in the therapeutic applications of SSRIs.

• Researchers in Pediatric Urology, Clinical Pharmacology, and Translational Medicine.

• Medical Students and Postgraduate Learners are interested in clinical trial design and pediatric research.

• Healthcare Professionals involved in multidisciplinary pediatric care.

Research Team

The study was conducted by a distinguished research team from the Department of Urology, Mansoura Urology and Nephrology Center, Mansoura University, including Dr. Mohamed Hussiiny, Prof. Abdelwahab Hashem, Dr. Mohamed A. Soltan, Dr. Tamer E. Helmy, Dr. Mahmoud R. El-Kenawy, and Prof. Ahmed Abdelhalim.